Skip to content
Lower risk Drug recall · FDA · Published December 13, 2019

Memantine Capsules Recall: Failed Dissolution Specifications Risk

The Harvard Drug Group recalls 28mg Memantine Hydrochloride Extended-release Capsules due to failed dissolution specifications observed in stability studies. This may affect medication effectiveness.

🇺🇸 FDA recall #D-0844-2020DrugThe Harvard Drug Group ›
Take action

Contact the company

Recalling firmThe Harvard Drug Group17177 N Laurel Park Dr Ste 233 · Livonia, MI 48152-3951
✎ GovInfoNow plain-language explainer

The Harvard Drug Group is recalling 28mg Memantine Hydrochloride Extended-release Caps: the product failed dissolution tests during stability studies, which could mean it doesn't work as intended. This is a medication recall for people prescribed this drug. Read more at govinfonow.com/recall/37656-memantine-capsules-recall-failed-dissolution-specifications-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/37656-memantine-capsules-recall-failed-dissolution-specifications-risk · Updated October 5, 2026 · FDA enforcement record: FDA #D-0844-2020

Cite this page

“Memantine Capsules Recall: Failed Dissolution Specifications Risk.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37656-memantine-capsules-recall-failed-dissolution-specifications-risk. Based on FDA recall #D-0844-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0844-2020%22&limit=1).

The Harvard Drug Group recalled Memantine Hydrochloride Extended-release Capsules, 28mg, due to failed dissolution specifications, the FDA said on Dec. 13, 2019. The recall involves 246 cartons distributed nationwide and is classified as Class III.

How to tell if you have it

  • Brand: The Harvard Drug Group
  • Product: Memantine Hydrochloride Extended-release Capsules, 28mg
  • Packaging: 100-count Unit Dose Cartons
  • NDC: 0904-6735-61
  • Lot Code: M02465D
  • Quantity: 246 Cartons

The hazard

The recall was issued because high out-of-specification results were observed at stability studies for the capsules. The FDA classified this as a Class III recall.

Context

GovInfoNow's records show The Harvard Drug Group has 20 other recalls on record since July 15, 2016. Other recent recalls include Harvard Drug Group Recalls Tramadol Tablets Due to Packaging Defect (June 16, 2023) and Harvard Drug Group Recalls Gabapentin Tablets Due to Foreign Tablet Mixup (April 24, 2023). Similar recent recalls of similar products include Harvard Drug Group Memantine Capsules Recall: Failed Dissolution Specifications (March 24, 2026), AvKARE Amantadine Capsules Recall: Failed Dissolution Specifications (Feb. 13, 2026), and Sun Pharmaceutical Lisdexamfetamine Capsules Recall: Failed Dissolution Test (Oct. 28, 2025).

How to tell if you have this one

Check for Memantine Hydrochloride Extended-release Capsules 28mg in 100-count Unit Dose Cartons. The product was manufactured by Lupin Pharmaceuticals and distributed by Major Pharmaceuticals. Lot number M02465D is associated with this recall.

  • Brand
    The Harvard Drug Group
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the product name, strength (28mg), and packaging (100-count Unit Dose Cartons) to confirm if it matches the recalled item.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “U.S.A. Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 11 months after the firm started it.

1. Firm started the recall: Dec 13, 201912. FDA classified it Class III: Feb 14, 202023. Published in FDA’s Enforcement Report: Feb 26, 202034. FDA terminated the recall: Nov 4, 2020420192020
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0844-2020 (December 13, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0844-2020 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA